

Improving Members' Outcomes Across the Continuum of Diabetes: Assessing the Impact of New Measures, Technologies, and Benefit Design Strategies

This supplement to *The American Journal of Managed Care* contains information on improving outcomes in diabetes through the appropriate use of new technologies and innovative benefit design strategies.

■ Faculty

Andrew J. Ahmann, MD, MS

Associate Professor of Medicine
Division of Endocrinology, Diabetes
and Clinical Nutrition
Oregon Health and Science University
Director, Diabetes Care Center
Portland, Oregon

Jan Berger, MD, MJ

Senior Vice President
Chief Clinical Officer
Caremark Inc
North Brook, Illinois

Lawrence Blonde, MD, FACP, FACE

Director
Ochsner Diabetes Clinical Research Unit
Section on Endocrinology, Diabetes,
and Metabolism
Associate Residency Program Director
Department of Internal Medicine
Ochsner Clinic Foundation
New Orleans, Louisiana

Curtis L. Triplitt, PharmD, CDE

Assistant Professor
Department of Medicine
Division of Diabetes
Clinical Assistant Professor of Pharmacy
Clinical Pharmacy Program
University of Texas Health Science Center
San Antonio, Texas

■ Faculty Disclosures

These participants report relationships with the following pharmaceutical companies:

Andrew J. Ahmann, MD, MS

Consultant:

The Amylin-Lilly Alliance
Ortho-Clinical Diagnostic
sanofi-aventis

Speaker's Bureau:

The Amylin-Lilly Alliance
Novo Nordisk
sanofi-aventis

Jan Berger, MD, MJ

Stockholder/Employee:

Caremark

Lawrence Blonde, MD, FACP, FACE

Research Funding:

Amylin
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
MannKind Corporation
Merck
Novartis
Novo Nordisk
Pfizer
sanofi-aventis

Consultant and Speaker:

Abbott
Amylin
Eli Lilly
GlaxoSmithKline
Lifescan
Merck/Schering-Plough
Novartis
Pfizer
sanofi-aventis

Speaker:

Takeda
Wyeth

Consultant:

AstraZeneca

Curtis L. Triplitt, PharmD, CDE

Speaker:

Novartis Pharmaceuticals
Pfizer Inc
sanofi-aventis

Advisory Board:

Amylin

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by pharmaceutical companies disclose any real or apparent conflicts of interest.

It is the policy of BCME to require the disclosure of any financial relationships or other relationships that a faculty member has with the manufacturers of any commercial products or providers relevant to the topics or therapeutic areas being discussed.

STAFF DISCLOSURES

BCME staff members and reviewers involved in clinical content development have no relevant financial relationships to disclose.

BCME has received educational grants from **The Amylin-Lilly Alliance** for CE/CME activities.

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Princeton, New Jersey.

Improving Members' Outcomes Across the Continuum of Diabetes: Assessing the Impact of New Measures, Technologies, and Benefit Design Strategies

This CME activity was planned and produced in accordance with the Accreditation Council for Continuing Medical Education Essential Areas and Policies.

ACTIVITY OVERVIEW

This activity will update participants on the state of diabetes in the United States, including epidemiology, consensus guidelines, and performance measures designed to evaluate and improve management of this population. This activity will ensure that managed care professionals are informed about new and investigational pharmacotherapeutic agents and technologies in the diabetes armamentarium. New benefit design strategies and their potential application to this disease state will be discussed, explored, and debated.

TARGET AUDIENCE

This activity is for managed healthcare professionals, especially pharmacy directors and medical directors, with an interest in improving members' outcomes in diabetes through the appropriate use of new technologies and innovative benefit design strategies.

EDUCATIONAL OBJECTIVES

After completing this educational supplement, the participant should be able to:

- Describe some of the current gaps in the management of diabetes in the US healthcare system.
- Recognize current standards of care for the management of diabetes and available quality improvement initiatives to help optimize health outcomes.
- Evaluate new and emerging diabetes technologies and classes of medications to determine their appropriate place in therapy.
- Analyze the potential impact of novel pharmacy benefit designs in diabetes management.

ACCREDITATION AND CREDIT DESIGNATION



The Bimark Center for Medical Education (BCME) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (No. 799).

This program is acceptable for 2.0 hours (0.2 CEU) of continuing education credit in states that recognize ACPE-accredited providers. The ACPE Universal Program Number for this program is 799-000-07-002-H01.



The BCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

BCME designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

COMMERCIAL SUPPORT

This activity is supported by an educational grant from **Amylin Pharmaceuticals** and **Eli Lilly and Company**.

Initial Release Date: **April 1, 2007**

Expiration Date: **April 1, 2008**

DISCLOSURE OF UNLABELED/UNAPPROVED USES OF DRUGS OR DEVICES

Participants are advised that some of the discussions in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices, and are indicated as such throughout the activity.



The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.